Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs
NCT06101342Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Dec 2023
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
A Phase 2 trial of lenacapavir in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Dec 2023; status: active, not recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06101342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06101342.